Introduction to Sanofi and Genzyme

Similar documents
SOL, ARGENTINA POMPE DISEASE. This is Genzyme

Join our scientific talent community

Genzyme s Multiple Sclerosis Franchise Featured at AAN

Orphan Pharma: pathfinders for an increasingly specialised industry

Abt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

Annual Report on Form 20-F

Cegedim Half-year results 2009 September 2009

Profile of Biomedical Research and Biotechnology Commercialization. Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area

ZENTIVA A SANOFI COMPANY. Corporate Presentation

Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH

Life Sciences Outlook. Boston 2015

Presented at: Jefferies 2015 Global Healthcare Conference

Creating Joint Value. In Biopharma and Many Other Industries, Not Invented Here Is SO Last Century. By Ben Gomes-Casseres

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

2015 Russian Nanotechnology Investment Enabling Technology Leadership Award

Groundbreaking Collaborative Clinical Trial Launched

What Lies Ahead? Trends to Watch: Health Care Product Development in North America

Life Sciences Outlook. New Jersey 2015

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry

Medical Equipment Monthly Deals Analysis: January M&A and Investment Trends

Sector Analysis February 4, 2016

EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston

Kelley Executive Certificate in the Business of Life Sciences Is this your year to move ahead?

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report

Technology and Expertise Add Operational Value to Medical Device Trials

Regulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG

THE VIRAL HEPATITIS CONGRESS September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme

Introduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act)

Background and Company Performance Industry Challenges Product Family Attributes and Business Impact Conclusion...

Increasing Innovation in R&D - Seizing early stage external growth opportunities

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C Report of Foreign Private Issuer

The Cell Therapy Catapult

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

Medical & Surgical Devices for Children: MDUFA IV Public Meeting. July 13, Tamar Magarik Haro Associate Director Dept. of Federal Affairs

METROWEST MEDICAL CENTER

Specialty Pharmacy? Disclosure. Objectives Technician

Children's Hospital Boston - Strategic SWOT Analysis Review

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles

Treating Refractory Hematological Malignancies Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011

Richard T. Clark Chief Executive Officer and President. Executing on Our Strategy

Winter Changing landscapes, pipeline products and plan sponsor impact

LEARN MORE AT: AROC puts DO Physicians within your reach!

Inviting Possibilities. Healthcare. Cover Page- Healthcare Sector Report.indd 1

Inventory of Access and Prices of Orphan Drugs across Europe:

MSC IN MEDICINAL CHEMISTRY

Roche Position on Human Stem Cells

From Research Services and Process Development to GMP Manufacturing

Around the Corner or Around the World

Chapter: 2 Health care Industry in India

Clinical trials: The EU perspective. Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission

5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned

ELITech Group - Product Pipeline Analysis

VNS CHOICE: Managing Complex Care Needs for the Frail Elderly of New York City. Roberta Brill Vice President, VNS Health Plans

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

Oncology Spotlight Early Commercialization Case Study. Susie Newton RN, MS, AOCN, AOCNS: Senior Director Quintiles Health Management Solutions

ACCELERATING BIOTECHNOLOGY INNOVATION

Healthcare, Regulatory and Reimbursement Landscape - Australia

Overview of the Specialty Drug Trend

Opportunities for Emerging Vaccine Markets

BIOTECHNOLOGY. Bouvé College of Health Sciences College of Science. Networked for Success. Networked for Industry. Networked for Life.

BEST PRACTICES RESEARCH

PlantForm Corporation

Investors' Access. Market. Strategic. Forum. Open. E-Health PROGRAM Alliance. Innovation PRELIMINARY. Management

MEDICAL DEVICE & DIAGNOSTICS

Rutgers Mini-MBA : BioPharma Innovation

ACINO SWITZERLAND. Delivering Health Ensuring Effective Relief

THE GABOR DANIELFY SCHOLARSHIP FOR HEALTHCARE COMPLIANCE & ETHICS

Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies

STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016

STATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder

NEUROSCIENCE. THE POWER OFxTM. Experts. Experience. Execution. Medpace Neuroscience Expertise. medpace.com

Specialty Pharmacy. Business Plan. July 8, RUSH University Medical Center

Administrative Organization

Making healthcare run more effectively

novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Protein Technologies Diabetes Protein Delivery Devices

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet

Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum

Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy

Transcription:

Introduction to Sanofi and Genzyme 495/MetroWest Partnership's Conference Panel December 15, 2015 Michelle Multiple Sclerosis Denmark

Overview Who is Sanofi? Who is Genzyme MetroWest Investment Talent Real Estate Community Relations 2

Who is Sanofi? Sanofi is a global healthcare leader focused on patients needs: engaged in the research, development, manufacturing and marketing of therapeutic solutions focused on patients needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. 4 th largest pharmaceutical group in the world Headquartered in France 3

SANOFI AT A GLANCE More than 110,000 employees Present in 100 countries Our mission We act with our partner to protect health, enhance life and respond to the hopes and potential healthcare needs of 7 billion people around the word. 3 Commitments Exploring the boundaries of medical innovation for patients Preventing disease and supporting patients Improving access to healthcare 33.8 million In sales 2014 3 business segments Pharma Human vaccines Animal Health CORPORATE PRESENTATION 2015 4

PHARMA HUMAN VACCINES ANIMAL HEALTH SANOFI AT A GLANCE OUR 3 BUSINESS SEGMENTS > Diabetes > Cardiovascular disease > Rare diseases > Multiple sclerosis > Oncology > Consumer Health care > Generics > Pediatric vaccines > Influenza vaccines > Booster vaccines for adults and adolescents > Meningitis vaccines >Vaccines for travelers and endemic areas PHARMA PRODUCTS > Anti-parasitics > Anti-infectives > Anti-inflammatories > Anti-ulceratives VACCINES > Foot and mouth disease > Rabies and pets vaccines Range > Avian vaccines Net sales 27,720 M Net sales 3,974 M Net sales 2,076 M G. Blonsky/Capa Pictures CORPORATE PRESENTATION 2015 5

GROWTH PLATFORMS Emerging markets Diabetes solutions Vaccines Consumer Healthcare Animal Health Genzyme Other Innovative Products 33.8 million In sales in 2014 112 Industrial sites in 41 countries present in more than 100 countries more than 110 000 employees R&D A major biopharmacy player 45% of revenues generated by biologics 80% of development projects are biologics Information of December 31 st 2013

Who is Genzyme? A pioneer of the biotechnology movement in the early 1980s, Genzyme has always been driven by cutting-edge science and a commitment to treating unmet medical needs. Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). We have also expanded through both in-house development and strategic acquisitions and partnerships to other disease areas such as thyroid cancer and multiple sclerosis 7 Generated 2,604 million in Sales for 2014, an increase of 24%

Rare Diseases Lysosomal Storage Disorders (LSDs) are the cornerstone of Genzyme's rare disease business Leverage our legacy to expand our expertise in additional therapeutics areas Innovative partnership with Alnylam focused on RNAi Sol Pompe disease Eva & Alberto Fabry disease THEREAPEUTIC AREAS Hematology Nephrology Neurology Pediatric Endocrinology Other TREATMENT AREAS Gaucher disease type 1 Pompe disease MPS I & II disease Fabry disease Thyroid cancer Homozygous Familial Hypercholesterolemia

Multiple Sclerosis Shani MS Tiger MS Once-daily oral therapy for relapsing remitting MS Infusion therapy for relapsing remitting MS 2 annual treatment courses MS business unit launched with the approval of two new therapies in 2013 Unique, personalized approach to patient care Strong early-stage MS pipeline focused on targeted immunomodulation, neuroprotection, remylenation, and progressive MS

MA Landscape: Genzyme s Impact Sanofi Genzyme is the largest Bio-Pharma employer in Massachusetts, with a combined 5,000 Sanofi Genzyme employees. Genzyme consistently ranks as one of the top charitable companies in Massachusetts, leading the Bio-Pharma industry. Genzyme s footprint stretches beyond the traditional center of Kendall Square, with sites in Allston, Framingham, Westborough and Northborough. 10

Sanofi Genzyme MetroWest Facts! Located in 19 buildings 2300 full time employees Real estate capacity to support an additional ~1100 employees Dedicated R&D Center and Manufacturing Operations Top 3 sources of talent finding: Internal Referral Direct Filled ~370 of the ~540 open positions 2015 11

Genzyme Northborough Operation Center (gnoc) Located in Northborough, Massachusetts Nearly 20 Acres of property with a 20 year lease. Over 200,000 square feet of warehouse space, fully equipped to meet the growth of Genzyme and meeting Quality standards Approximately 200 employees 13

gnoc Facts Total Size: 254,095 sq ft 2 TSA Certified Cargo Screening Areas 24/7 Full-Perimeter Security 2 Megawatt Diesel Backup Generator Materials Operations Warehouse 134,813 sq ft CRT 4,350 pallets 2-8C 791 pallets -20C 316 pallets Receiving 9 docks Shipping 6 docks Offices 1,202 sq ft Clinical Supplies Warehouse CRT Offices 10,160 sq ft 654 pallets 5,923 sq ft Quality Control Raw Materials Warehouse 10,197 sq ft CRT 480 pallets Lab 3,200 sq ft Sampling suite 2,000 sq ft Office 4,326 sq ft Labeling & Packaging GroupPackaging Suite 9,194 sq ft 2-8C 500 sq ft Offices 5,923 sq ft 14

Cerezyme Fabrazyme Myozyme / Lumizyme Clolar Thyrogen Aldurazyme Elaprase SepraFilm LeGoo Hyaluronic Acid (HA) Materials Support

Genzyme in Westborough Moved into One Research Drive from Framingham on November 21, 2014 500 employees working across multiple functions: Genzyme Industrial Operations Global Leadership and support functions Genzyme Corporate Quality Operations and Global Quality Leadership Sanofi Information Solutions Sanofi Human Resources (including Staffing) Sanofi Regulatory Affairs and Procurement Employee Volunteerism

Community Relations Our Community Relations mission is to have a lasting positive impact where our employees live and work, by building sustainable partnerships through a combination of financial contributions and employee involvement. Employee Volunteerism Health+ Access Good Neighbors Science Education

Dedicated and Committed Community Relations Mission in MetroWest! In 2014, Genzyme awarded ~$125,000 in grants/sponsorships to MetroWest Organizations Genzyme Science Kids program at Fuller Middle School Boys and Girls Club of MetroWest Big Brothers Big Sisters of Central Mass MetroWest Community Farms Outreach Family Promise MetroWest Framingham Public Library Habitat for Humanity of MetroWest/Worcester MetroWest Free Medical Program Ashland Fire Department Association 18

19 Thank You!